Marketwire -- London, UK; Brentwood, TN, US: 14 August 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, announces that on 13
August 2008, in accordance with the Transparency Obligations
Directive, a notification of interest in the ordinary share capital of
the Company was received from AXA Investment Managers UK Limited on
behalf of AXA S.A. and its Group Companies ("AXA"). The notification
follows an increase in its Indirect Voting Rights. Details of
the interest notified are as follows:
